ERD-3111

ERD-3111 (Compound 44) is an orally active PROTAC ERα degrader (DC50: 0.5 nM) . ERD-3111 inhibits tumor growth in the parental MCF-7 xenograft model with wild-type ER and two clinically relevant ESR1 mutated mice model. ERD-3111 can be used in the research of ER+ breast cancer[1].

Product Specifications

CAS Number

[2832865-25-3]

UNSPSC

12352005

Target

Estrogen Receptor/ERR; PROTACs

Type

Reference compound

Related Pathways

PROTAC; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/erd-3111.html

Purity

98.72

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(CN1[C@@H](CC2=C([C@H]1C3=C(C=C(C=C3F)N4CCC5(CC4)CCN(C(CN6CC(C=C(C7=C8)C(N(C7=O)C9CCC(NC9=O)=O)=O)=C8C6)=O)CC5)F)C=CC%10=C2C=NN%10)C)F

Molecular Formula

C45H46F4N8O5

Molecular Weight

854.89

References & Citations

[1]Chen Z, et al. Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity. J Med Chem. 2023 Aug 30.